S&P 500   3,911.40 (-0.31%)
DOW   31,235.26 (-0.81%)
QQQ   291.10 (-0.01%)
AAPL   140.27 (-0.39%)
MSFT   255.45 (+0.54%)
FB   192.61 (+0.19%)
GOOGL   2,239.43 (+0.06%)
AMZN   2,179.55 (+1.74%)
TSLA   706.38 (-0.48%)
NVDA   172.57 (+1.88%)
BABA   87.28 (-0.03%)
NIO   16.38 (+3.47%)
AMD   98.22 (+2.01%)
CGC   5.73 (+2.50%)
MU   70.64 (-0.58%)
T   20.18 (-0.25%)
GE   75.11 (-0.12%)
F   12.80 (+0.16%)
DIS   104.64 (+0.33%)
AMC   13.11 (+2.74%)
PFE   49.78 (-1.23%)
PYPL   79.17 (+2.58%)
NFLX   181.14 (+2.23%)
S&P 500   3,911.40 (-0.31%)
DOW   31,235.26 (-0.81%)
QQQ   291.10 (-0.01%)
AAPL   140.27 (-0.39%)
MSFT   255.45 (+0.54%)
FB   192.61 (+0.19%)
GOOGL   2,239.43 (+0.06%)
AMZN   2,179.55 (+1.74%)
TSLA   706.38 (-0.48%)
NVDA   172.57 (+1.88%)
BABA   87.28 (-0.03%)
NIO   16.38 (+3.47%)
AMD   98.22 (+2.01%)
CGC   5.73 (+2.50%)
MU   70.64 (-0.58%)
T   20.18 (-0.25%)
GE   75.11 (-0.12%)
F   12.80 (+0.16%)
DIS   104.64 (+0.33%)
AMC   13.11 (+2.74%)
PFE   49.78 (-1.23%)
PYPL   79.17 (+2.58%)
NFLX   181.14 (+2.23%)
S&P 500   3,911.40 (-0.31%)
DOW   31,235.26 (-0.81%)
QQQ   291.10 (-0.01%)
AAPL   140.27 (-0.39%)
MSFT   255.45 (+0.54%)
FB   192.61 (+0.19%)
GOOGL   2,239.43 (+0.06%)
AMZN   2,179.55 (+1.74%)
TSLA   706.38 (-0.48%)
NVDA   172.57 (+1.88%)
BABA   87.28 (-0.03%)
NIO   16.38 (+3.47%)
AMD   98.22 (+2.01%)
CGC   5.73 (+2.50%)
MU   70.64 (-0.58%)
T   20.18 (-0.25%)
GE   75.11 (-0.12%)
F   12.80 (+0.16%)
DIS   104.64 (+0.33%)
AMC   13.11 (+2.74%)
PFE   49.78 (-1.23%)
PYPL   79.17 (+2.58%)
NFLX   181.14 (+2.23%)
S&P 500   3,911.40 (-0.31%)
DOW   31,235.26 (-0.81%)
QQQ   291.10 (-0.01%)
AAPL   140.27 (-0.39%)
MSFT   255.45 (+0.54%)
FB   192.61 (+0.19%)
GOOGL   2,239.43 (+0.06%)
AMZN   2,179.55 (+1.74%)
TSLA   706.38 (-0.48%)
NVDA   172.57 (+1.88%)
BABA   87.28 (-0.03%)
NIO   16.38 (+3.47%)
AMD   98.22 (+2.01%)
CGC   5.73 (+2.50%)
MU   70.64 (-0.58%)
T   20.18 (-0.25%)
GE   75.11 (-0.12%)
F   12.80 (+0.16%)
DIS   104.64 (+0.33%)
AMC   13.11 (+2.74%)
PFE   49.78 (-1.23%)
PYPL   79.17 (+2.58%)
NFLX   181.14 (+2.23%)
NYSEAMERICAN:CVM

CEL-SCI (CVM) Stock Forecast, Price & News

$2.98
-0.08 (-2.61%)
(As of 05/19/2022 10:14 AM ET)
Add
Compare
Today's Range
$2.96
$3.14
50-Day Range
N/A
52-Week Range
$2.49
$27.28
Volume
2,787 shs
Average Volume
1.43 million shs
Market Capitalization
$128.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.1
30 days | 90 days | 365 days | Advanced Chart
Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CEL-SCI logo

About CEL-SCI

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Headlines

See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:CVM
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$560 thousand
Book Value
$1.31 per share

Profitability

Net Income
$-36.36 million
Pretax Margin
-115,637.94%

Debt

Price-To-Earnings

Miscellaneous

Free Float
37,795,000
Market Cap
$128.96 million
Optionable
Optionable

Company Calendar

Last Earnings
5/16/2022
Today
5/19/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

1.01 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

Are investors shorting CEL-SCI?

CEL-SCI saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,420,000 shares, an increase of 27.6% from the April 15th total of 7,380,000 shares. Based on an average daily trading volume, of 1,770,000 shares, the days-to-cover ratio is presently 5.3 days.
View CEL-SCI's Short Interest
.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for CEL-SCI
.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) released its earnings results on Monday, May, 16th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.07.
View CEL-SCI's earnings history
.

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

CEL-SCI shares reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's key executives?
CEL-SCI's management team includes the following people:
  • Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 63, Pay $675.65k)
  • Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 71, Pay $270.05k)
  • Dr. Eyal Talor Ph.D., Chief Scientific Officer (Age 66, Pay $320.86k)
  • Dr. Daniel H. Zimmerman Ph.D., Sr. VP of Research & Cellular Immunology (Age 81, Pay $249.01k)
  • Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 80, Pay $225.36k)
What other stocks do shareholders of CEL-SCI own?
What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.63%), Vanguard Group Inc. (4.78%), State Street Corp (2.27%), Renaissance Technologies LLC (1.79%), D.A. Davidson & CO. (0.99%) and Northern Trust Corp (0.81%). Company insiders that own CEL-SCI stock include Eyal Talor, Geert R Kersten, John Cipriano, Peter R Young and Robert Eugene Watson.
View institutional ownership trends for CEL-SCI
.

Which institutional investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Simplex Trading LLC, Walleye Trading LLC, GSA Capital Partners LLP, BlackRock Inc., Qube Research & Technologies Ltd, Group One Trading L.P., and Virtu Financial LLC.
View insider buying and selling activity for CEL-SCI
or view top insider-selling stocks.

Which institutional investors are buying CEL-SCI stock?

CVM stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Goldman Sachs Group Inc., Walleye Capital LLC, Advisor Group Holdings Inc., Dimensional Fund Advisors LP, D.A. Davidson & CO., Cutter & CO Brokerage Inc., and Allspring Global Investments Holdings LLC. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Peter R Young, and Robert Eugene Watson.
View insider buying and selling activity for CEL-SCI
or or view top insider-buying stocks.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $3.06.

How much money does CEL-SCI make?

CEL-SCI has a market capitalization of $132.42 million and generates $560 thousand in revenue each year. The company earns $-36.36 million in net income (profit) each year or ($0.930010) on an earnings per share basis.

How many employees does CEL-SCI have?

CEL-SCI employs 2,020 workers across the globe.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at (703) 506-9460, via email at [email protected], or via fax at 703-506-9471.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.